"The greatest risk of hubris to human health comes in the form of antibiotic-resistant bacteria"- The World Economic Forum's Global Risks 2013
“Antimicrobial resistance is one of the three greatest threats to human health”- World Health Organization
AntibioTx receives funding from The Advanced Technology Foundation
AntibioTx receives funding from Novo A/S
Promising results against C. difficile
In vivo proof-of-concept against S. aureus
Promising results against P. acnes
AntibioTx receives grant from Innovation Fund Denmark
Final formulation of ATx201 shows promising human skin penetration
Promising results against MRSA
AntibioTx is a privately held pharmaceutical company dedicated to the development of a novel class of antibiotics to treat bacterial infections and related disorders that are currently causing harm to millions of patients worldwide.
AntibioTx has a fully operational lab and has utilized cutting edge systems biology and screening methods to identify and characterize a potential game changing class of antibiotics.
The mission of AntibioTx is to develop and commercialize groundbreaking antibiotics to overcome antibiotic resistance and fight infectious diseases. The need for novel antibiotics has been emphasized repeatedly as the evolution of antibiotic resistance continues. AntibioTx is committed to developing and marketing a portfolio of innovative antibiotics capable of addressing highly resistant infections and unmet medical needs.
The AntibioTx-class is differentiated from current antibiotics in several ways:
Bacterial infections are a leading cause of death worldwide and the relentless evolution of antimicrobial resistance renders currently available antibiotics ineffective at an increasing pace. Recent studies estimate that by 2050, antibiotic resistance could lead to as many as 10 million mortalities annually and societal costs in excess of 100 trillion USD.
Antibiotic resistance is a natural evolutionary phenomenon wherein bacteria prevent an antibiotic from working against an infection. Antibiotics and antimicrobial drugs have been used since the 1930’s to treat patients suffering from infectious diseases. However, due to their prolonged use, infectious organisms develop resistance towards antibiotics. Over the course of several years, improper use and misuse of antibiotics have led to a dramatic increase in the number of antibiotic resistant bacteria. Today, antibiotic resistance is an alarming global problem charged by the spread of bacteria across the world.
The reasons for the development of antibiotic resistance are complex and while most current antibiotics are on the verge of becoming ineffective against resistant strains of bacteria, very few efforts are being taken to develop newer and more effective antibiotics.
Over the past 40 years, only two new antibiotic classes have been brought to patients. Public healthcare systems and drug developers have been relying on analogues of existing antibiotics, but due to rapid emergence of renewed resistance to analogues of already challenged antibiotics, this approach has failed to address the threat from multi-drug resistance. To overcome this threat, new classes of antibiotics are needed.
AntibioTx has identified, characterized, and patent protected a new class of antibiotics. The class of antibiotics has broad applicability against pathogens and infections. Additionally, it is significantly de-risked due to decades of safe use for non-related purposes. AntibioTx has outlined a broader pipeline, but is currently focused on three lead candidates: ATx201, ATx202 and ATx401.
ATx201 has shown excellent potential against clinically relevant isolates of Staphylococus aureus including methicillin-resistant strains. Research shows that ATx201 confers a very low frequency of mutations and has shown outstanding antibacterial properties in animal models. Studies also reveal that ATx201 achieves high local concentrations at relevant human skin layers without any significant absorption of compound through the skin. ATx201 is a small molecule that is well characterized and has been used for human treatment for decades without ever being deployed for antibacterial purposes. AntibioTx have indications of mechanism of action, but additional work is required for a complete understanding. ATx201 is being developed for the topical treatment of bacterial skin infections.
ATx202 exhibits outstanding properties for the treatment of acne in terms of in vitro spectrum of effect and delayed onset of de novo resistance. Furthermore, the molecule has properties that are suitable for cutaneous delivery and long-term treatment which qualifies our belief that ATx202 can offer a superior treatment for more than 140 million patients in target countries who suffer from acne.
AntibioTx has identified a compound with strong effect against C. difficile. According to extensive microbiological characterization, ATx401 inhibits spore formation in C. difficile at a fixed level compared to the minimum inhibitory concentration.
The global market opportunity for the three current pipeline priorities is in excess of 10 Billion USD annually and could potentially provide treatment to more than 200 million patients suffering for a variety of infectious and related diseases.
For each indication, there are significant unmet medical needs that represent a strong match with small molecule treatment and the characteristics of AntibioTx’s pipeline programs.
With a group of innovative employees, encompassing rich expertise in identification of new antibiotics and early stage development, AntibioTx is committed to improving the health of humans suffering from multidrug resistant infections.
Rasmus has experience in business development from positions in a family enterprise, which was sold in 2005, management consulting at Booz Allen Hamilton and investment banking at Goldman Sachs and Gudme Raaschou.
Rasmus has a strong entrepreneurial inclination and has been involved with new ventures across a number of industries including co-founding two biotech companies.
Rasmus holds a degree in finance and business administration from Copenhagen Business School and New York University and an executive degree in entrepreneurial leadership from Harvard Business School.
Morten Sommer is the founder of four biotech companies, including Microlytic founded in 2006 and serves over 150 customers, including 9 of the 10 largest pharmaceutical companies in the world. The company was sold in a cross-border transaction in 2015.
Morten is also a Professor at the Technical University of Denmark with a lab of 25 PhD's and Post docs working primarily in the field of antibiotic resistance. Morten is the inventor on 10+ issued patents, patent applications and author of scientific papers in journals such as Science and Nature.
Dr. Sommer holds a Ph.D. in Biophysics from Harvard University from the laboratory of Professor George Church.
Daniel has extensive experience with anti-infective research from academia and in leadership roles in the pharmaceutical industry. Before joining AntibioTx, Daniel was leading the Microbial Pathogenicity Laboratory at GSK and prior to that, he was the Head of Bacterial Genetics at Baxter Vaccine.
Daniel holds a Ph.D. in Microbiology from Paris Diderot University and has been an Assistant Professor in the Department of Microbiology and Immunology at Drexel University College of Medicine and an Assistant Professor in the Department of Microbiology and Immunology at Uniformed Services University of the Health Sciences.
Jan Trofast is the co-inventor of AstraZeneca’s blockbuster Symbicort, which is currently generating annual revenues of 4 Billion USD.
In addition to being an inventor, Jan is the strategist behind a highly successful patent portfolio of 25+ patents protecting Symbicort and related products. Symbicort is expected to become AstraZeneca’s best-selling drug despite core patent expiration.
Jan Trofast has more than 30 years of experience from AstraZeneca including a number of years with evaluation of internal and external projects. Jan Trofast obtained a Ph.D. in Organic Chemistry from Lund University in 1978.
AntibioTx constantly seeks like-minded and talented drug developers, scientists, and business developers at any level who share our passion for improving the health of humans suffering from multi-drug resistant infections.
We offer fast-paced, non-bureaucratic, merit-based career opportunities in a field with potentially life-saving results; applying deep knowledge of antibacterials, resistance mechanisms, cutting-edge advances in modern systems biology, microbiome insights, computational power and pharmaceutical expertise in a collaborative spirit to solve one of the greatest challenges of our time.
Please submit your motivation and CV to email@example.com if you are ready to eliminate resistance for a better human health.
Kogle Allé 5
Phone: +45 61777435
The Ruth Group
Att. Tram Bui & Lee Roth
757 Third Avenue, Floor 26
New York, NY 10017
United States of America
Phone: +1 646-536-7035 / +1 646-536-7012
Email: firstname.lastname@example.org / email@example.com